Medartis
Medartis AG, headquartered in Switzerland (CH), is a leading player in the medical device industry, specialising in innovative solutions for the treatment of bone fractures and deformities. Founded in 1997, the company has established a strong presence in Europe, Asia, and the Americas, focusing on advanced surgical techniques and high-quality implants. Medartis is renowned for its unique product offerings, including the patented locking plate systems and comprehensive range of surgical instruments designed for orthopaedic and trauma surgery. These products are distinguished by their precision engineering and commitment to enhancing patient outcomes. With a solid market position, Medartis has achieved significant milestones, including numerous regulatory approvals and partnerships with healthcare professionals worldwide, solidifying its reputation as a trusted provider in the orthopaedic sector.
DitchCarbon Score
How does Medartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medartis's score of 59 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medartis's reported carbon emissions
In 2024, Medartis reported total carbon emissions of approximately 2,682,931 kg CO2e, comprising 877,100 kg CO2e from Scope 1, 752,450 kg CO2e from Scope 2, and 1,053,211 kg CO2e from Scope 3 emissions. The Scope 3 emissions included significant contributions from upstream transportation and distribution (368,760 kg CO2e) and waste generated in operations (382,260 kg CO2e). Medartis has set ambitious climate commitments, aiming for a 60% reduction in absolute Scope 1 and 2 emissions by 2033, compared to 2023 levels. This target is supported by external verification to ensure accountability. Additionally, the company has committed to a long-term goal of achieving a 90% reduction in Scope 1 and 2 emissions by 2050. For Scope 3 emissions, Medartis aims to reduce emissions from capital goods, upstream transportation and distribution, waste generated in operations, employee commuting, and end-of-life treatment of sold products by 61.1% per million CHF value added by 2033. Furthermore, the company plans for 67% of its suppliers to have science-based targets by 2029. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Medartis's commitment to sustainable practices within the healthcare equipment and supplies sector. The emissions data and reduction targets are inherited from Medartis Holding AG, ensuring a cohesive approach to climate action across the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 795,000 | 000,000 | 000,000 |
| Scope 2 | 831,000 | 000,000 | 000,000 |
| Scope 3 | 689,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
